Emergent BioSolutions

+$0.42 (+1.30%) Today
$0.00 (0.00%) As of 12:00 AM UTC after-hours

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell EBS and other ETFs, options, and stocks.

About EBS

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats.

CEO
Robert G. Kramer
Employees
2,416
Headquarters
Gaithersburg, Maryland
Founded
1998

EBS Key Statistics

Market cap
1.65B
Price-Earnings ratio
11.29
Dividend yield
—
Average volume
675.18K
High today
$33.15
Low today
$31.97
Open price
$32.62
Volume
782.99K
52 Week high
$68.03
52 Week low
$26.85

EBS News

BenzingaJun 24

U.S. FDA Accepts Emergent's Anthrax Vaccine Candidate Filing For Review

The U.S. Food and Drug Administration (FDA) has accepted to review Emergent BioSolutions’ EBS Biologics License Application (BLA) for its new anthrax vaccine ca
MarketWatchJun 24

UPDATE: Emergent BioSolutions says FDA has accepted its anthrax vaccine candidate for review

Emergent BioSolutions Inc. EBS, +7.19% said Friday the U.S. Food and Drug Administration has accepted for review its application for approval of its anthrax vac
MarketWatchJun 24

Emergent BioSolutions: FDA to Review AV7909 Anthrax Vaccine Candidate - MarketWatch

By Colin Kellaher Emergent BioSolutions Inc. on Friday said the Food and Drug Administration accepted for review its application seeking approval of its anthra

EBS Earnings

-$0.36
$1.26
$2.88
$4.50
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Q4 FY21
Q1 FY22
Q2 FY22
Estimated
— per share
Actual
Expected Jul 28, After Hours
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure